- Home
- NRC vs HQL Comparison
NRC vs HQL Comparison
Compare NRC & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- HQL
- Stock Information
- Founded
- NRC 1981
- HQL 1992
- Country
- NRC United States
- HQL United States
- Employees
- NRC N/A
- HQL N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- HQL Investment Managers
- Sector
- NRC Health Care
- HQL Finance
- Exchange
- NRC Nasdaq
- HQL Nasdaq
- Market Cap
- NRC 426.3M
- HQL 391.1M
- IPO Year
- NRC N/A
- HQL N/A
- Fundamental
- Price
- NRC $19.46
- HQL $13.80
- Analyst Decision
- NRC
- HQL
- Analyst Count
- NRC 0
- HQL 0
- Target Price
- NRC N/A
- HQL N/A
- AVG Volume (30 Days)
- NRC 83.2K
- HQL 120.9K
- Earning Date
- NRC 10-25-2024
- HQL 01-01-0001
- Dividend Yield
- NRC 2.51%
- HQL 11.56%
- EPS Growth
- NRC N/A
- HQL N/A
- EPS
- NRC 1.12
- HQL 0.79
- Revenue
- NRC $144,155,000.00
- HQL N/A
- Revenue This Year
- NRC N/A
- HQL N/A
- Revenue Next Year
- NRC N/A
- HQL N/A
- P/E Ratio
- NRC $16.70
- HQL $17.08
- Revenue Growth
- NRC N/A
- HQL N/A
- 52 Week Low
- NRC $17.62
- HQL $11.34
- 52 Week High
- NRC $42.19
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- NRC 50.39
- HQL 33.42
- Support Level
- NRC $18.33
- HQL $13.70
- Resistance Level
- NRC $21.64
- HQL $14.37
- Average True Range (ATR)
- NRC 0.79
- HQL 0.27
- MACD
- NRC 0.01
- HQL -0.10
- Stochastic Oscillator
- NRC 38.24
- HQL 7.10
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.